The US Food and Drug Administration has given a warning letter to Dr Reddy’s Laboratories Ltd over inadequate quality control procedures at three manufacturing plants in India.

FDA has issued the warning letter to Dr Reddy’s on Thursday for its Srikakulam, Miryalaguda and Duvvada drug manufacturing plants, all based in southern India.

Dr Reddy’s said in a statement that the letter followed FDA inspections of these sites in November, January and February, and the company will respond to the agency in 15 days.

GV Prasad, Dr Reddy’s Chief Executive said that “We will continue to actively engage with the agency to resolve these issues.”

Read EquityPandit’s Technical Analysis Of Indian Stock Market